DOCSLIB.ORG

Cannabis in the Workplace

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabis in the Workplace Cannabis in the Workplace Ryan Vandrey, PhD Johns Hopkins University School of Medicine Disclosures • Paid consultant to Zynerba Pharmaceuticals, Battelle Memorial Institute • None of my consulting is directly related to the work I will present • Funding for the studies provided by the Substance Abuse and Mental Health Services Administration (SAMHSA) Current State Laws Workplace Implications • What are the effects of cannabis? • What kind of impairment can be expected? • How can we detect cannabis use? • Does product type or route impact effects? • Is there a biomarker for impairment? • What about secondhand exposure? • Can/should you test for legal cannabis use? • What about treatment for problematic use? Acute Effects • Positive: Euphoria, relaxed, easier to laugh, increased appetite, potential medical benefit • Negative: rapid heart rate, dry mouth, red and irritated eyes, paranoia, anxiety, nausea/vomiting, hallucinations, cognitive impairment (memory, attention, time estimation, complex cognition) • Driving impairment: increased risk for accident, impairment on vehicle following, lane position, and emergency maneuvers Chronic Use Effects • Cannabis Use Disorder; tolerance/withdrawal • Increased rate of mental health problems • Decreased memory, attention, IQ • Cannabinoid Hyperemesis Syndrome • Altered brain structure; Age of onset important • Unclear if effects are reversed with abstinence • Correlations only; cannot infer causality • Functional significance not well established; difficult to determine “fit for duty” impact Cannabis and the Workplace • 62% of the workforce in the U.S. lives in a state where medical use of cannabis is legal • 21% of the workforce in the U.S. lives in a state where adult non-medical use of cannabis is legal • Rates of use are higher in states where cannabis is legal versus those where it is not Incident Treatment Admissions Approximately 21% of U.S. Percentage of FT workers adults 18 and older entering who indicated their primary substance treatment for the drug at admission was… first time reported their employment status as full-time Marijuana 17.2% (FT) on the 2012 Treatment Episode Dataset (TEDS). Prescription drugs 12.2% 21% Illicit drugs 9.5% Federal Guidelines • SAMHSA Mandatory Guidelines for workplace drug testing • Living document outlining regulations for workplace drug testing • SAMHSA Division of Workplace Programs • Current cannabis test standard: EIA screen: 50ng/mL GC/MS confirmation: 15 ng/mL • Oral fluid and hair testing in development SAMHSA Research • Primary interest in PK to inform federal workplace drug testing • Incorporated subjective, cardiovascular, performance assessments • Enrolled non-tolerant healthy adults • Varied route of administration and dose • Same protocol across studies • Evaluation of sex differences • Ensuring consistent/complete dose delivery Dosing • Cannabis obtained from NIDA • Passive, vaporized, ingested, smoked • PL, 10mg, 25mg, and 50mg* doses * Oral administration only Assessments 2 14 Biological Specimens • Whole blood: THC, 11-OH-THC, and THCCOOH (LOQ = 0.5ng/mL) • Urine: THCCOOH (LOQ = 0.75ng/mL) • Saliva/oral fluid: THC and THCCOOH (LOQ = 2 and 0.02 ng/mL respectively) Passive Exposure Study • 3 test sessions; 12 participants per session 5.3% THC cannabis; no ventilation 11% THC cannabis; no ventilation 11% THC cannabis; ventilation • 6 smokers (ad-lib) and 6 passively exposed • 60-minute exposure period Test Chamber Effect of Ventilation Can I Get a Contact High? Can I Get a Contact High? PK/PD Summary • Urine: Cmax, 2-11 hrs; >15 ng/mL, 2-30 hrs • OF: Cmax = 0.25 hr; > 4 ng/mL, 0.25-2 hrs • Blood: Cmax = 0.25-2 hrs; Two > 5 ng/mL • Room ventilation has a significant impact on secondhand smoke exposure • Under extreme circumstances, intoxication and positive drug tests can occur • Likelihood of positive test depends on the biological matrix and cut-offs used Oral Administration • Study 1: Pharmacokinetic Emphasis - 3 doses of cannabis - Between subjects design - Assessments over 9 days (PD on Day 1) • Study 2: Pharmacodynamic Emphasis - 3 doses plus placebo - Within-subjects crossover design - PK/PD for 8 hours post-administration Study 1 Methods • 18 healthy adults recruited - Prior cannabis use; not in past 3 months • 6-days residential; 3-days outpatient • Single dose of cannabis administered Day 1 - Whole plant cannabis baked into brownies with 10, 25, or 50mg THC - 3M/3F administered each dose • Standard low-fat breakfast provided Drug Preparation • Cannabis ground into powder • Heated for 30 min at 250°F (121°C) • Individual doses stirred into brownie batter and baked for 30 min at 325°F (163°C) Urine PK Oral Cannabis, THCCOOH, Urine 600 THCCOOH Mean UR, 10 mg 500 THCCOOH Mean UR, 25 mg 400 THCCOOH Mean UR, 50 mg 300 15 ng/mL Cutoff ng/mL 200 100 0 0 50 100 150 200 25 Hours Urine PK UR Cmax, Oral Cannabis (THCCOOH) UR Detection Times, Last Positive 1200 15 ng/mL, Oral Cannabis (THCCOOH) 10 mg 25 mg 50 mg 200 1000 10 mg 25 mg 50 mg 800 150 600 100 Hours ng/mL 400 50 200 0 0 1 2 3 4 5 6 Mean 1 2 3 4 5 6 Mean Subjects Dosed Subjects Dosed 26 Oral Fluid THC Oral Cannabis, THC, Oral Fluid 1000 THC Mean OF 10 mg 750 THC Mean OF 25 mg THC Mean OF 50 mg 500 ng/mL 250 0 0 2 4 6 Hours 27 Oral Fluid THCCOOH Oral Cannabis, THCCOOH, Oral Fluid 250 THCCOOH Mean OF 10 mg 200 THCCOOH Mean OF 25 mg 150 THCCOOH Mean OF 50 mg 50 pg/mL Cutoff pg/mL 100 50 0 0 50 100 Hours 28 Whole Blood THC Oral Cannabis, THC, Blood 3 2 THC Mean BL, 10 mg THC Mean BL, 25 mg ng/mL 1 THC Mean BL, 50 mg 2 ng/mL Cutoff 0 0 6 12 18 24 30 Hours 29 Whole Blood 11-OH-THC Oral Cannabis, 11-OH-THC, Blood 4 11-OH THC Mean BL, 10 mg 11-OH THC Mean BL, 25 mg 3 11-OH THC Mean BL, 50 mg 2 ng/mL 1 0 0 6 12 18 24 30 Hours 30 Whole Blood THCCOOH Oral Cannabis, THCCOOH, Blood 30 THCCOOH Mean BL, 10 mg THCCOOH Mean BL, 25 mg 20 THCCOOH Mean BL, 50 mg ng/mL 10 0 0 40 80 120 Hours 31 Oral Administration • THC = Passive • THC = Smokers at baseline • Drug Effect much greater Oral PK Summary URINE • Long detection times for THCCOOH ORAL FLUID • Short detection times for THC • THCCOOH was erratic BLOOD • Very low cannabinoid concentrations • 2/6 at 50 mg THC dose had 5 ng/mL peak • 2/6 at 10 mg did not have detectable THC • Moderate correlation with VAS Drug Effect, but not performance impairment Study 2 Methods • 17 healthy adults (9M, 8F) - Prior cannabis use; not in past month - No cannabis use between sessions • 4 outpatient sessions; 1 week between • Within-subjects crossover design - 10, 25, and 50mg THC doses - Placebo = 250mg cannabis < 1% THC • Standard low-fat breakfast provided VAS: Drug Effect * * * VAS: Good Effect * * * VAS: Unpleasant Effect * * Other Subjective Effects • Increased ratings of Tired/Sleepy, Heart Racing, Nervous/Anxious, Hungry/Have Munchies; Decreased rating of Alert following 25 and 50mg doses • Increased ratings of Paranoid, Irritable, Sick and Restless at 50mg dose Heart Rate * * DSST: # Correct * * PASAT: # Correct * * Div Attention: Tracking * * PK/PD Correlations PK/PD Correlations Oral PD Summary • Orderly dose effects observed across pharmacodynamic measures • 25mg and 50mg THC doses consistently different from placebo; subjective intoxication and performance impairment evident • 10mg THC dose generally not different from placebo on negative effects • Greater drug effects for females on select outcomes Smoke Vs. Vapor • 17 healthy adults (9M, 8F) - Prior cannabis use; not in past month - No cannabis use between sessions • 6 outpatient sessions; 1 week between • Within-subjects crossover design - PL, 10, and 25mg THC doses - Clustered by route, counterbalanced - Random order within route • Standard low-fat breakfast provided Drug Administration • Smoked: exact dose of cannabis placed in pipe; covered; participants instructed to smoke entire contents ad-lib; checked for completion by pharmacist • Vaporized: exact dose of cannabis placed in Volcano vaporizer; Temp set to 400°F (204°C); opaque bag covered “balloon”; participant inhaled 3 “balloons” ad-lib VAS: Drug Effect 100 100 Smoked Vaporized 90 90 Smoke PL Vape PL 80 Smoke 10mg 80 Vape 10mg 70 Smoke 25mg 70 Vape 25mg 60 60 50 50 40 40 30 30 20 20 10 10 0 0 -1 0.16 0.5 1 1.5 2 3 4 5 6 8 -1 0.16 0.5 1 1.5 2 3 4 5 6 8 Hours Hours VAS: Good Effect 100 100 90 Smoked 90 Vaporized Smoke PL Vape PL 80 Smoke 10mg 80 Vape 10mg 70 Smoke 25mg 70 Vape 25mg 60 60 50 50 40 40 30 30 20 20 10 10 0 0 -1 0.16 0.5 1 1.5 2 3 4 5 6 8 -1 0.16 0.5 1 1.5 2 3 4 5 6 8 Hours Hours VAS: Unpleasant Effect 100 100 90 Smoked 90 Vaporized Smoke PL Vape PL 80 Smoke 10mg 80 Vape 10mg 70 Smoke 25mg 70 Vape 25mg 60 60 50 50 40 40 30 30 20 20 10 10 0 0 -1 0.16 0.5 1 1.5 2 3 4 5 6 8 -1 0.16 0.5 1 1.5 2 3 4 5 6 8 Hours Hours Heart Rate 100 100 Smoked Vaporized 95 Smoke PL 95 Vape PL Smoke 10mg Vape 10mg 90 90 Smoke 25mg Vape 25mg 85 85 80 80 75 75 70 70 65 65 60 60 -1 0.16 0.5 1 1.5 2 3 4 5 6 8 -1 0.16 0.5 1 1.5 2 3 4 5 6 8 Hours Hours DSST: # Correct 60 60 58 Smoked 58 Vaporized 56 56 54 54 52 52 50 50 48 48 46 46 Smoke PL Vape PL 44 44 Smoke 10mg Vape 10mg 42 Smoke 25mg 42 Vape 25mg 40 40 -1 0.5 1 1.5 2 3 4 5 6 8 -1 0.5 1 1.5 2 3 4 5 6 8 Hours Hours PASAT: # Correct 90 90 Smoked Vaporized 85 85 80 80 75 75 70 70 Smoke PL Vape PL 65 Smoke 10mg 65 Vape 10mg Smoke 25mg Vape 25mg 60 60 -1 0.5 1 1.5 2 3 4 5 6 8 -1 0.5 1 1.5 2 3 4 5 6 8 Hours Hours Div Attention: Tracking 60 60 55 Smoked 55 Vaporized Smoke PL Vape PL 50 50 Smoke 10mg Vape 10mg 45 Smoke 25mg 45 Vape 25mg 40 40 35 35 30 30 25 25 20 20 15 15 10 10 -1 0.5 1 1.5 2 3 4 5
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,515,007 B2 Murad (45) Date of Patent: Feb
    USOO6515007B2 (12) United States Patent (10) Patent No.: US 6,515,007 B2 Murad (45) Date of Patent: Feb. 4, 2003 (54) METHODS FOR MANAGING SCALP OTHER PUBLICATIONS CONDITIONS WPIDS AN 1997-389337, JP 09 169638 A, Jun. 30, 1997, (76) Inventor: Howard Murad, 4265 Marina City Dr., bstract.* Penthouse 11, Marina del Rey, CA (US) MEDLINE 79172521, Orfanos et al, Hautarzt, Mar. 1979, 90292 30(3), 124–33, abstract.* * cited by examiner (*) Notice: patentSubject is to extended any disclaimer, or adjusted the term under of this 35 Primary Examiner Rebecca Cook U.S.C. 154(b) by 0 days. (74) Attorney, Agent, or Firm-Pennie & Edmonds LLP (57) ABSTRACT (21) Appl. No.: 09/920,729 ThisS applicationCO relatesCLCSO to a ph CCUCtical compositionCOOOSOO f (22) Filed: Aug. 3, 2001 the prevention, treatment, and management of Scalp O O conditions, Such as dandruff, Seborrheic dermatitis, (65) Prior Publication Data pSoriasis, folliculitis, and hair thinning including a thera US 2002/0009423 A1 Jan. 24, 2002 peutically effective amount of an acidic component of a hydroxyacid or tannic acid, or a pharmaceutically acceptable Related U.S. Application Data Salt thereof. A preferred anti-dandruff composition and - - - method of managing dandruff includes a therapeutically (62) Pisie of Epitol N: SE filed R Aug. 5. effective amount of the acid component, a vitamin A application, now Nolog23,484Pat. No. O.Z f 1,240,filedonii. which 27, is 1998,a division now Pat o OPO and an anti-growthi- agent. A preferred anti-hairi-hai No. 6,207,694. thinning composition and method of managing thinning hair 7 includes a therapeutically effective amount of the acidic (51) Int.
    [Show full text]
  • An Overview On: Sublingual Route for Systemic Drug Delivery
    International Journal of Research in Pharmaceutical and Biomedical Sciences ISSN: 2229-3701 __________________________________________Review Article An Overview on: Sublingual Route for Systemic Drug Delivery K. Patel Nibha1 and SS. Pancholi2* 1Department of Pharmaceutics, BITS Institute of Pharmacy, Gujarat Technological university, Varnama, Vadodara, Gujarat, India 2BITS Institute of Pharmacy, Gujarat Technological University, Varnama, Vadodara, Gujarat, India. __________________________________________________________________________________ ABSTRACT Oral mucosal drug delivery is an alternative and promising method of systemic drug delivery which offers several advantages. Sublingual literally meaning is ''under the tongue'', administrating substance via mouth in such a way that the substance is rapidly absorbed via blood vessels under tongue. Sublingual route offers advantages such as bypasses hepatic first pass metabolic process which gives better bioavailability, rapid onset of action, patient compliance , self-medicated. Dysphagia (difficulty in swallowing) is common among in all ages of people and more in pediatric, geriatric, psychiatric patients. In terms of permeability, sublingual area of oral cavity is more permeable than buccal area which is in turn is more permeable than palatal area. Different techniques are used to formulate the sublingual dosage forms. Sublingual drug administration is applied in field of cardiovascular drugs, steroids, enzymes and some barbiturates. This review highlights advantages, disadvantages, different sublingual formulation such as tablets and films, evaluation. Key Words: Sublingual delivery, techniques, improved bioavailability, evaluation. INTRODUCTION and direct access to systemic circulation, the oral Drugs have been applied to the mucosa for topical mucosal route is suitable for drugs, which are application for many years. However, recently susceptible to acid hydrolysis in the stomach or there has been interest in exploiting the oral cavity which are extensively metabolized in the liver.
    [Show full text]
  • Chapter 1 Controlling Drug Delivery
    chapter 1 Controlling drug delivery Overview In this chapter we will: & differentiate drug delivery systems according to their physical state & differentiate drug delivery systems according to their route of administration & differentiate drug delivery systems according to their type of drug release & discuss drug transport across epithelial barriers. Introduction KeyPoints & Continued developments in Pharmacotherapy can be defined as the treatment chemistry, molecular biology and prevention of illness and disease by means of and genomics support the drugs of chemical or biological origin. It ranks discovery and developments among the most important methods of medical of new drugs and new drug treatment, together with surgery, physical targets. & treatment, radiation and psychotherapy. There The drug delivery system are many success stories concerning the use of employed can control the pharmacological action of a drugs and vaccines in the treatment, prevention drug, influencing its and in some cases even eradication of diseases pharmacokinetic and (e.g. smallpox, which is currently the only subsequent therapeutic human infectious disease completely profile. eradicated). Although it is almost impossible to estimate the exact extent of the impact of pharmacotherapy on human health, there can be no doubt that pharmacotherapy, together with improved sanitation, better diet and better housing, has improved people’s health, life expectancy and quality of life. Tip Unprecedented developments in genomics Combinatorial chemistry is a way to and molecular biology today offer a plethora of build a variety of structurally related new drug targets. The use of modern chemical drug compounds rapidly and synthetic methods (such as combinatorial systematically. These are assembled chemistry) enables the syntheses of a large from a range of molecular entities number of new drug candidates in shorter times which are put together in different ‘ ’ than ever before.
    [Show full text]
  • Delivery of Orally Administered Digestible Antibodies Using Nanoparticles
    International Journal of Molecular Sciences Review Delivery of Orally Administered Digestible Antibodies Using Nanoparticles Toshihiko Tashima Tashima Laboratories of Arts and Sciences, 1239-5 Toriyama-cho, Kohoku-ku, Yokohama, Kanagawa 222-0035, Japan; [email protected] Abstract: Oral administration of medications is highly preferred in healthcare owing to its simplicity and convenience; however, problems of drug membrane permeability can arise with any administra- tion method in drug discovery and development. In particular, commonly used monoclonal antibody (mAb) drugs are directly injected through intravenous or subcutaneous routes across physical barri- ers such as the cell membrane, including the epithelium and endothelium. However, intravenous administration has disadvantages such as pain, discomfort, and stress. Oral administration is an ideal route for mAbs. Nonetheless, proteolysis and denaturation, in addition to membrane impermeability, pose serious challenges in delivering peroral mAbs to the systemic circulation, biologically, through enzymatic and acidic blocks and, physically, through the small intestinal epithelium barrier. A num- ber of clinical trials have been performed using oral mAbs for the local treatment of gastrointestinal diseases, some of which have adopted capsules or tablets as formulations. Surprisingly, no oral mAbs have been approved clinically. An enteric nanodelivery system can protect cargos from proteolysis and denaturation. Moreover, mAb cargos released in the small intestine may be delivered to the systemic circulation across the intestinal epithelium through receptor-mediated transcytosis. Oral Abs in milk are transported by neonatal Fc receptors to the systemic circulation in neonates. Thus, well-designed approaches can establish oral mAb delivery. In this review, I will introduce the imple- mentation and possibility of delivering orally administered mAbs with or without nanoparticles not Citation: Tashima, T.
    [Show full text]
  • Soft Gelatin Capsules)
    ERGOCALCIFEROL- ergocalciferol capsule Blenheim Pharmacal, Inc. ---------- VITAMIN D, ERGOCALCIFEROL Capsules, USP, 1.25 mg SOFTGEL CAPSULES (Soft Gelatin Capsules) (50,000 USP Units) Rx Only DESCRIPTION Ergocalciferol Capsules, USP is a synthetic calcium regulator for oral administration. Ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils. It is affected by air and by light. Ergosterol or provitamin D 2 is found in plants and yeast and has no antirachitic activity. There are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic activity. One USP Unit of vitamin D 2 is equivalent to one International Unit (IU), and 1 mcg of vitamin D 2 is equal to 40 IU. Each softgel capsule, for oral administration, contains Ergocalciferol, USP 1.25 mg (equivalent to 50,000 USP units of Vitamin D), in an edible vegetable oil. Ergocalciferol, also called vitamin D 2 ,is 9, 10-secoergosta-5, 7,10(19),22-tetraen-3-ol,(3β,5 Z,7 E,22 E)-; (C 28H 44O) with a molecular weight of 396.65, and has the following structural formula: Inactive Ingredients: D&C Yellow #10, FD&C Blue #1, Gelatin, Glycerin, Purified Water, Refined Soybean Oil. CLINICAL PHARMACOLOGY The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxy- vitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization.
    [Show full text]
  • Drug Administration
    Chapter 3: Drug Administration 2 Contact Hours By: Katie Ingersoll, RPh, PharmD Author Disclosure: Katie Ingersoll and Elite do not have any actual or Questions regarding statements of credit and other customer service potential conflicts of interest in relation to this lesson. issues should be directed to 1-888-666-9053. This lesson is $12.00. Universal Activity Number (UAN): 0761-9999-17-079-H01-P Educational Review Systems is accredited by the Activity Type: Knowledge-based Accreditation Council of Pharmacy Education (ACPE) Initial Release Date: April 1, 2017 as a provider of continuing pharmaceutical education. Expiration Date: April 1, 2019 This program is approved for 2 hours (0.2 CEUs) of Target Audience: Pharmacists in a community-based setting. continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 To Obtain Credit: A minimum test score of 70 percent is needed weeks to participants who have successfully completed the post-test. to obtain a credit. Please submit your answers either by mail, fax, or Participants must participate in the entire presentation and complete online at Pharmacy.EliteCME.com. the course evaluation to receive continuing pharmacy education credit. Learning objectives After completion of this course, healthcare professionals will be able Discuss the administration of medications in patients using enteral to: and parenteral nutrition. Describe the eight rights of medication administration. Discuss special considerations for administering medications in Explain the administration of enteral and parenteral medications. pediatric and geriatric patients. Introduction Medication errors that occur at the point of drug administration poised to reduce the frequency of medication administration errors.
    [Show full text]
  • A Survey of Cannabis Consumption and Implications of an Experimental Policy Manipulation Among Young Adults
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2018 A SURVEY OF CANNABIS CONSUMPTION AND IMPLICATIONS OF AN EXPERIMENTAL POLICY MANIPULATION AMONG YOUNG ADULTS Alyssa K. Rudy Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd © The Author Downloaded from https://scholarscompass.vcu.edu/etd/5297 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. A SURVEY OF CANNABIS CONSUMPTION AND IMPLICATIONS OF AN EXPERIMENTAL POLICY MANIPULATION AMONG YOUNG ADULTS A thesis proposal submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by Alyssa Rudy B.S., University of Wisconsin - Whitewater, 2014 Director: Dr. Caroline Cobb Assistant Professor Department of Psychology Virginia Commonwealth University Richmond, Virginia January, 2018 ii Acknowledgement I would like to first acknowledge Dr. Caroline Cobb for your guidance and support on this project. Thank you for allowing me to explore my passions. I am thankful for your willingness to jump into an unfamiliar area of research with me, and thank you for constantly pushing me to be a better writer, researcher, and person. I would also like to acknowledge the other members of my thesis committee, Drs. Eric Benotsch and Andrew Barnes for their support and expertise on this project. I would also like to thank my family for always supporting my desire to pursue my educational and personal goals.
    [Show full text]
  • Oral Films: a Comprehensive Review
    Mahboob et al., International Current Pharmaceutical Journal, November 2016, 5(12): 111-117 International Current http://www.icpjonline.com/documents/Vol5Issue12/03.pdf Pharmaceutical Journal REVIEW ARTICLE OPEN ACCESS Oral Films: A Comprehensive Review *Muhammad Bilal Hassan Mahboob1,2, Tehseen Riaz1,2, Muhammad Jamshaid1, Irfan Bashir1,2 and Saqiba Zulfiqar1,2,3 1Faculty of Pharmacy, University of Central Punjab Lahore, Pakistan 2Foundation for Young Researchers, Pakistan 3Shoukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan ABSTRACT In the late 1970s, rapid disintegrating drug delivery system was developed as an alternative to capsules, tablets and syrups for geriatric and pediatric patients having problems in swallowing. To overcome the need, number of orally disintegrating tablets which disinte- grate within one minute in mouth without chewing or drinking water were commercialized. Then later, oral drug delivery technology had been improved from conventional dosage form to modified release dosage form and developed recently rapid disintegrating films rather than oral disintegrating tablets. Oral disintegrating film or strips containing water dissolving polymer retain the dosage form to be quickly hydrated by saliva, adhere to mucosa, and disintegrate within a few seconds, dissolve and releases medication for oro- mucosal absorption when placed in mouth. Oral film technology is the alternative route with first pass metabolism. This review give a comprehensive detail of materials used in ODF, manufacturing process, evaluation tests and marketed products. Key Words: Oral disintegrating film, oral strip, pediatric and geriatric patients. INTRODUCTIONINTRODUCTION An oral film or strips are manufactured as a large Oral administration is the most preferred route due to re- sheet and then cut into individual dosage unit for packag- lieve of ingestion, pain reduction, to accommodate various ing (Desai et al., 2012).
    [Show full text]
  • An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics
    children Review An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics Nirnoy Dan, Kamalika Samanta and Hassan Almoazen * Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA; [email protected] (N.D.); [email protected] (K.S.) * Correspondence: [email protected]; Tel.: +1-(901)-448-2239 Received: 28 October 2020; Accepted: 16 December 2020; Published: 19 December 2020 Abstract: While each route of therapeutic drug delivery has its own advantages and limitations, oral delivery is often favored because it offers convenient painless administration, sustained delivery, prolonged shelf life, and often lower manufacturing cost. Its limitations include mucus and epithelial cell barriers in the gastrointestinal (GI) tract that can block access of larger molecules including Therapeutic protein or peptide-based drugs (TPPs), resulting in reduced bioavailability. This review describes these barriers and discusses different strategies used to modify TPPs to enhance their oral bioavailability and/or to increase their absorption. Some seek to stabilize the TTPs to prevent their degradation by proteolytic enzymes in the GI tract by administering them together with protease inhibitors, while others modify TPPs with mucoadhesive polymers like polyethylene glycol (PEG) to allow them to interact with the mucus layer, thereby delaying their clearance. The further barrier provided by the epithelial cell membrane can be overcome by the addition of a cell-penetrating peptide (CPP) and the use of a carrier molecule such as a liposome, microsphere, or nanosphere to transport the TPP-CPP chimera. Enteric coatings have also been used to help TPPs reach the small intestine.
    [Show full text]
  • A Focus Group Study About Oral Drug Administration Practices at Hospital Wards—Aspects to Consider in Drug Development of Age-Appropriate Formulations for Children
    pharmaceutics Article A Focus Group Study about Oral Drug Administration Practices at Hospital Wards—Aspects to Consider in Drug Development of Age-Appropriate Formulations for Children Maria Rautamo 1,2,3,*, Kirsi Kvarnström 1,2, Mia Sivén 2 , Marja Airaksinen 2, Pekka Lahdenne 4 and Niklas Sandler 3 1 HUS Pharmacy, HUS Helsinki University Hospital, Stenbäckinkatu 9B, 00290 Helsinki, Finland; kirsi.kvarnstrom@hus.fi 2 Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, University of Helsinki, 00014 Helsinki, Finland; mia.siven@helsinki.fi (M.S.); marja.airaksinen@helsinki.fi (M.A.) 3 Pharmaceutical Sciences Laboratory, Åbo Akademi University, Tykistökatu 6A, 20520 Turku, Finland; [email protected] 4 Department of Children and Adolescents, HUS Helsinki University Hospital, Stenbäckinkatu 9, 00029 Helsinki, Finland; pekka.lahdenne@hus.fi * Correspondence: maria.rautamo@helsinki.fi or maria.rautamo@hus.fi Received: 11 January 2020; Accepted: 27 January 2020; Published: 30 January 2020 Abstract: Oral drug administration to pediatric patients is characterized by a lack of age-appropriate drug products and the off-label use of medicines. However, drug administration practices at hospital wards is a scarcely studied subject. The aim of this study was to explore the oral drug administration practices at pediatric hospital wards, with a focus on experiences and challenges faced, methods used to mitigate existing problems, drug manipulation habits, perceptions about oral dosage forms and future needs of oral dosage forms for children. This was a qualitative study consisting of focus group discussions with physicians, nurses and clinical pharmacists in a tertiary university hospital with the objective of bringing forward a holistic view on this research topic.
    [Show full text]
  • Challenges of Dissolution Methods Development for Soft Gelatin Capsules
    pharmaceutics Review Challenges of Dissolution Methods Development for Soft Gelatin Capsules Festo Damian 1, Mohammad Harati 2, Jeff Schwartzenhauer 3, Owen Van Cauwenberghe 1,4 and Shawn D. Wettig 1,5,* 1 School of Pharmacy, University of Waterloo, 200 University Ave W, Waterloo, ON N2L 3G1, Canada; [email protected] (F.D.); [email protected] (O.V.C.) 2 Department of Natural Sciences, University of Michigan, 2209 Natural Sciences Building, 4901 Evergreen Rd, Dearborn, MI 48128, USA; [email protected] 3 Catalent Pharma Solutions, 2125 Ambassador Dr, Windsor, ON N9C 3R5, Canada; [email protected] 4 Bio Therapeutic Molecules Inc., 70 Southgate Drive, Unit 4, Guelph, ON N1G 4P5, Canada 5 Waterloo Institute for Nanotechnology, University of Waterloo, 200 University Ave W, Waterloo, ON N2L 3G1, Canada * Correspondence: [email protected]; Tel.: +1-519-888-4567 (ext. 42221) Abstract: Recently, the development of soft gelatin capsules (SGCs) dosage forms has attracted a great deal of interest in the oral delivery of poorly water-soluble drugs. This is attributed to the increased number of poorly soluble drugs in the pipeline, and hence the challenges of finding innovative ways of developing bioavailable and stable dosage forms. Encapsulation of these drugs into SGCs is one of the approaches that is utilized to deliver the active ingredients to the systemic circulation to overcome certain formulation hurdles. Once formulated, encapsulated drugs in the form of SGCs require suitable in vitro dissolution test methods to ensure drug product quality and Citation: Damian, F.; Harati, M.; Schwartzenhauer, J.; Van performance. This review focuses on challenges facing dissolution test method development for Cauwenberghe, O.; Wettig, S.D.
    [Show full text]
  • Accuracy of Enteral Syringes with Commonly Prescribed Paediatric
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Accuracy of enteral syringes with commonly prescribed paediatric oral liquid medicines Arenas-Lopez S, Gurung K, Tibby SM, Calleja-Hernandez MA, Tuleu C Sara Arenas-López, Consultant Pharmacist Paediatric Critical Care, Evelina London Children’s Hospital, Guy’s & St Thomas NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH Tel: +442071885049 Email: [email protected] Karuna Gurung, MRPharm Student, UCL School of Pharmacy, London, United Kingdom Shane M Tibby, PICU Consultant, Evelina London Children’s Hospital, London SE1 7EH Email: [email protected] Miguel-Angel Calleja-Hernández, Director Pharmacy Service, Hospital Universitario Virgen de las Nieves and Professor at University of Granada, Spain. Email: [email protected] Catherine Tuleu (Corresponding author), Reader in Pharmaceutics, UCL School of Pharmacy, London, United Kingdom [email protected] Keywords: Accuracy-volume-enteral-syringes-liquid-paediatrics-device Word count – Original article: 2482 1 ABSTRACT (273 Words) Aim: To investigate the paediatric volumetric accuracy for two enteral syringe brands, using commercially available liquid drug formulations, across a range of clinically relevant volumes and physicochemical properties. Method: In vitro experiment under laboratory conditions. Ten drug formulations were tested for two syringe brands (Baxa, Medicina) using a range of formulation volumes (0.05 to 5 mL) and syringe sizes (1 to 5 mL). The weight of syringes, empty, filled and after expelling liquids were accurately measured and converted into volume, based on the known formulation densities. Ten replications were performed for each combination of drug, syringe and volume.
    [Show full text]